Evidence map›Paper›PMID 23252909›Full record

ArticleAnnals of the New York Academy of Sciences2012

Animal models of antimuscle-specific kinase myasthenia.

David P Richman, Kayoko Nishi, Michael J Ferns, Joachim Schnier, Peter Pytel, Ricardo A Maselli, Mark A Agius

Abstract read
In one paragraph

Article in Annals of the New York Academy of Sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Muscle-Specific Kinase Myasthenia Gravis.Frontiers in immunology · 2020
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

David P RichmanDepartment of Neurology, Center for Neuroscience, University of California, Davis, 95616, USA. dprichman@ucdavis.edu
Kayoko Nishi
Michael J Ferns
Joachim Schnier
Peter Pytel
Ricardo A Maselli
Mark A Agius
Center for Neurosciences · USUniversity of Chicago · USVA Northern California Health Care System · US

Funding

Development of Animal Models of Anti-MuSK MyastheniaR21NS071325 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI RICHMAN, DAVID P · 2010 to 2011
$418k
NINDS NIH HHS R21 NS071325
6 · The paper itself

Abstract

Antimuscle-specific kinase (anti-MuSK) myasthenia (AMM) differs from antiacetylcholine receptor myasthenia gravis in exhibiting more focal muscle involvement (neck, shoulder, facial, and bulbar muscles) with wasting of the involved, primarily axial, muscles. AMM is not associated with thymic hyperplasia and responds poorly to anticholinesterase treatment. Animal models of AMM have been induced in rabbits, mice, and rats by immunization with purified xenogeneic MuSK ectodomain, and by passive transfer of large quantities of purified serum IgG from AMM patients into mice. The models have confirmed the pathogenic role of the MuSK antibodies in AMM and have demonstrated the involvement of both the presynaptic and postsynaptic components of the neuromuscular junction. The observations in this human disease and its animal models demonstrate the role of MuSK not only in the formation of this synapse but also in its maintenance.

Indexed as

AnimalsImmunoglobulin GMiceMuscle, SkeletalMyasthenia Gravis, Autoimmune, ExperimentalNeuromuscular JunctionRabbitsRatsReceptor Protein-Tyrosine KinasesImmunoglobulin GReceptor Protein-Tyrosine Kinases

Identifiers

PMID23252909
PMCPMC3915870
OpenAlexW1818736198

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.